MRSA Drugs - Global Market Trajectory & Analytics

Description Table of
Contents

LOGIN TO ACCESS EXECUTIVE SUMMARY
PRINTER FRIENDLY

Global MRSA Drugs Market to Reach $3.8 Billion by 2027

Amid the COVID-19 crisis, the global market for MRSA Drugs estimated at US$3.1 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 3% over the analysis period 2020-2027. Lipopeptide, one of the segments analyzed in the report, is projected to record a 1.7% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Oxazolidinone segment is readjusted to a revised 4.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $905.2 Million, While China is Forecast to Grow at 2.9% CAGR

The MRSA Drugs market in the U.S. is estimated at US$905.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$678.6 Million by the year 2027 trailing a CAGR of 2.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.8% and 2.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Cephalosporin Segment to Record 4.3% CAGR

In the global Cephalosporin segment, USA, Canada, Japan, China and Europe will drive the 4.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$359.3 Million in the year 2020 will reach a projected size of US$487.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$424.6 Million by the year 2027.

Select Competitors (Total 41 Featured):

Absynth Biologics
Allergan PLC
AmpliPhi Biosciences Corporation
AstraZeneca PLC
Basilea Pharmaceutica Ltd.
Baxter International, Inc.
Cempra, Inc.
CrystalGenomics Inc.
Debiopharm Group
Galapagos NV
GlaxoSmithKline plc
Innovation Pharmaceuticals Inc.
Kyorin Pharmaceutical Co., Ltd.
Lytix Biopharma AS
Melinta Therapeutics, Inc.
Merck & Co., Inc.
Nabriva Therapeutics US, Inc.
NovaDigm Therapeutics, Inc.
Paratek Pharmaceuticals, Inc.
Pfizer, Inc.
R-Pharm-US LLC
Savara Inc.
Sealife PHARMA GMBH
Sequella, Inc.
The Medicines Company
Theravance Biopharma, Inc.
XBiotech Inc.

Note: Product cover images may vary from those shown

LOGIN TO ACCESS EXECUTIVE SUMMARY
PRINTER FRIENDLY

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Current & Future Analysis for MRSA Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for MRSA Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for MRSA Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Lipopeptide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Lipopeptide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 6: World 15-Year Perspective for Lipopeptide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Oxazolidinone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 8: World Historic Review for Oxazolidinone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Oxazolidinone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 14: World Historic Review for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Tetracycline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 19: World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 22: World Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 23: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 24: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 25: USA Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 26: USA Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 27: USA 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 28: USA Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 29: USA Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 30: USA 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
CANADA
Table 31: Canada Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 32: Canada Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 33: Canada 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 34: Canada Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 35: Canada Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 36: Canada 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
JAPAN
Table 37: Japan Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 38: Japan Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 39: Japan 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 40: Japan Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 41: Japan Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 42: Japan 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
CHINA
Table 43: China Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 44: China Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 45: China 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 46: China Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 47: China Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 48: China 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
EUROPE
Table 49: Europe Current & Future Analysis for MRSA Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 50: Europe Historic Review for MRSA Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 51: Europe 15-Year Perspective for MRSA Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Table 52: Europe Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 53: Europe Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 54: Europe 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 55: Europe Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 56: Europe Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 57: Europe 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
FRANCE
Table 58: France Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 59: France Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 60: France 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 61: France Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 62: France Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 63: France 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
GERMANY
Table 64: Germany Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 65: Germany Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 66: Germany 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 67: Germany Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 68: Germany Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 69: Germany 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
ITALY
Table 70: Italy Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 71: Italy Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 72: Italy 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 73: Italy Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 74: Italy Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 75: Italy 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 76: UK Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 77: UK Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 78: UK 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 79: UK Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 80: UK Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 81: UK 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
REST OF EUROPE
Table 82: Rest of Europe Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 83: Rest of Europe Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 84: Rest of Europe 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 85: Rest of Europe Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 86: Rest of Europe Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 87: Rest of Europe 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Table 88: Asia-Pacific Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 89: Asia-Pacific Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 90: Asia-Pacific 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 91: Asia-Pacific Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 92: Asia-Pacific Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 93: Asia-Pacific 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
REST OF WORLD
Table 94: Rest of World Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 95: Rest of World Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 96: Rest of World 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
Table 97: Rest of World Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 98: Rest of World Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 99: Rest of World 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 41

Note: Product cover images may vary from those shown

RELATED TAGS

RELATED PRODUCTS

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Global Market Trajectory & Analytics

Complicated Skin And Soft Tissue Infections (cSSTI) - Pipeline Insight, 2021

Gram-positive Bacterial Infections Market - Growth, Trends, and Forecasts (2020 - 2025)

Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2021

Hospital Acquired Methicillin Resistant Staphylococcus aureus (HA-MRSA) Infections R&D Pipeline Analysis Report, Q4 2020